Proprietary, Patented, FDA-cleared, non-thermal energy technology built for clinical performance and long-term platform scale.
The GEN2 platform uses low-voltage direct current electrolysis to precisely coagulate tissue without thermal damage — a fundamentally different mechanism than traditional energy-based systems.
By avoiding thermal injury, the platform preserves surrounding tissue integrity while enabling precise, controlled treatment in minimally invasive clinical settings.
The platform is being enhanced to securely capture patient and procedural data in a HIPAA-compliant format, forming the foundation for future analytics, insights, and platform intelligence.

Medfiniti’s platform integrates treatment delivery with compliant data capture, creating a foundation that extends beyond a single procedure or device interaction.
This architecture enables a transition from isolated treatments to a connected clinical system — linking procedures, data, and future diagnostic capabilities within a unified platform.
Secure capture of patient and procedural data across devices and cloud infrastructure creates a structured record of clinical activity.
Structured datasets enable future AI-powered insights, supporting clinical decision-making, workflow optimization, and detection support.
The platform is positioned to expand into endoscopic and colorectal diagnostics, connecting treatment delivery with real-time diagnostic intelligence.
The Medfiniti platform is structured so that treatment, data, and intelligence layers evolve together — enabling long-term expansion without rebuilding core infrastructure.
Secure data handling across devices and cloud systems.
Treatment, data, and diagnostics integrated into one system.
Future applications leverage the same core infrastructure.